Qube Research & Technologies LTD An2 Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $61.9 Billion
- Q1 2024
A detailed history of Qube Research & Technologies LTD transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 50,365 shares of ANTX stock, worth $105,766. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,365
Previous 72,208
30.25%
Holding current value
$105,766
Previous $1.48 Million
88.98%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.27 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.27 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$2.92 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.6 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.56 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $40.7M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...